AVITA Medical Past Earnings Performance

Past criteria checks 0/6

AVITA Medical's earnings have been declining at an average annual rate of -2.5%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 37.2% per year.

Key information

-2.5%

Earnings growth rate

9.0%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate37.2%
Return on equity-72.1%
Net Margin-70.6%
Next Earnings Update13 May 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How AVITA Medical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:51KB Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2350-356621
30 Sep 2345-345917
30 Jun 2341-315317
31 Mar 2337-264815
31 Dec 2234-274514
30 Sep 2232-304415
30 Jun 2230-304314
31 Mar 2232-294115
31 Dec 2133-253816
30 Sep 2131-223415
30 Jun 2129-273715
31 Mar 2123-354213
31 Dec 2018-445011
30 Sep 2016-495411
30 Jun 2014-42499
31 Mar 2012-36438
31 Dec 1911-28357
30 Sep 198-23297
30 Jun 195-25288
31 Mar 194-22276
31 Dec 182-181710
30 Sep 181-151510
30 Jun 181-13166
31 Mar 181-12128
31 Dec 171-11127
30 Sep 171-10116
30 Jun 171-9115
31 Mar 171-8104
31 Dec 161-783
30 Sep 161-893
30 Jun 161-883
31 Mar 161-873
31 Dec 151-753
30 Sep 151-653
30 Jun 151-643
31 Mar 151-542
31 Dec 141-552
30 Sep 142-562
30 Jun 143-572
31 Mar 143-672
31 Dec 133-782
30 Sep 133-782
30 Jun 133-782

Quality Earnings: 51KB is currently unprofitable.

Growing Profit Margin: 51KB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 51KB is unprofitable, and losses have increased over the past 5 years at a rate of 2.5% per year.

Accelerating Growth: Unable to compare 51KB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 51KB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).


Return on Equity

High ROE: 51KB has a negative Return on Equity (-72.12%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.